Terrific trial results, COP tribulation, and a transaction: Rumin8’s 2025 establishes a strong base for 2026
Rumin8’s extensive trial program in 2025 and its plans for 2026 highlights its progress validating the efficacy and safety of its methane abatement solutions for livestock as it moves through regulatory approval pathways towards commercialisation.
Rumin8 conducted 17 separate animal trials across multiple product formats in 2025, with several of those trials now the subject of peer reviewed scientific publications and several additional publications due to be published shortly.
“There were three common threads linking every one of those trials,” said Rumin8 CEO David Messina. “First, the Rumin8 active group recorded substantial reductions in methane. Second, there were no residues of our bioactive detected in the tissues studied from the treated animals. Third, where we focused on productivity, the Rumin8 active group also recorded superior weight gains, compared to controls.
“Each of these results are fundamental to progressing the development, regulatory review, and ultimately the approval and safe commercialisation of Rumin8’s products. When combined with the inherent scalability, precise dosing and low cost of our pharmaceutical approach to methane abatement, Rumin8 provides a compelling value proposition for farmers and ranchers, while helping the planet.”
“And importantly, with more than 36 animal studies now completed with Rumin8 products, involving some of the world’s leading universities and research institutions, we are now entering the final phase of commercial scale testing and preparation of extensive food safety studies for regulatory approval.”
The trial work is key to delivering the efficacy and safety data necessary to support registration applications with regulators in Rumin8 target markets globally,’
Many of Rumin8’s planned 2026 studies will be conducted with industry leading partners to reflect standard feeding and finishing practices in feedlot and pasture production systems, involving hundreds of animals.
This transition to commercial scale testing will follow the completion of a pilot currently underway in Brazil (pictured), involving more than 250 cattle. The pilot has been conducted in partnership with Minerva Foods, one of the world’s largest food companies.
This pilot represents the first time that carbon credits will be generated from cattle fed with Rumin8’s methane abating and productivity enhancing feed additive. Monetising carbon abatement, while generating more meat or milk, is core to Rumin8’s value proposition for farmers and ranchers and is central to the product’s commercial adoption. Initial results will be available in the new year.
The Minerva/Rumin8 Pilot was highlighted on various panel sessions at the recent COP30 conference in Belem, Brazil (pictured). There was significant interest in the pilot and in Rumin8’s progress, ranging from animal health companies, global food companies and even large technology companies.
“It was gratifying to see that Rumin8’s work and progress is being monitored and appreciated by some of the world’s largest companies,” Mr Messina said.
Rumin8’s activities in 2025 have not been limited to field work and regulatory interactions. In December, Rumin8 announced the acquisition of ROAM Agricultural Pty Ltd, strengthening the company’s portfolio of methane abating solutions.
ROAM utilised same active ingredient as Rumin8, and importantly, has developed delivery formats that expand Rumin8’s portfolio to reach production systems that can benefit from an extended release profile.
“When you step back and look at our achievements in 2025, we have had a very busy year,” Mr Messina said. “And 2026 will be even busier.”